Physician profile
Sultan Mohammad
NPI 1760699888
$4,994.69
in general payments reported to CMS, 2019-2025
44 companies · $877 in 2025
The $877 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $596 · 2021: $1,006 · 2022: $656 · 2023: $676 · 2024: $692 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,231 · Entertainment: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,231.17 |
| Entertainment | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $732.65 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $576.78 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $324.30 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $298.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $285.63 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $272.78 | 2019-2025 | Veozah |
| Abbott Laboratories | $256.04 | 2020-2025 | Freestyle Libre 3, Proclaim, Octrode |
| Janssen Pharmaceuticals, INC | $171.41 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $141.16 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.07 | 2019-2025 | Xifaxan, Trulance |
| Shockwave Medical, INC | $128.60 | 2022 | |
| Boston Scientific Corporation | $126.08 | 2021-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Ucb, INC. | $117.96 | 2019-2021 | |
| Pfizer INC. | $110.60 | 2023-2025 | |
| Allergan, INC. | $109.72 | 2019-2020 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $108.99 | 2021-2024 | Gvoke Hypopen, Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $91.60 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.56 | 2025 | Lifevest |
| Merck Sharp & Dohme LLC | $71.19 | 2019-2020 | |
| Dexcom, INC. | $68.04 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $62.06 | 2024-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $56.94 | 2019-2021 | |
| Cequr Corporation | $56.15 | 2024 | Cequr Simplicity |
| Microtransponder, INC. | $56.03 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $54.82 | 2021 | |
| Lundbeck LLC | $53.05 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $50.79 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $43.11 | 2019-2020 | |
| Phadia US INC. | $41.70 | 2021-2023 | Immunocap |
| Mylan Specialty L.P. | $33.10 | 2020-2022 | |
| Medtronic, INC. | $31.99 | 2023 | Interstim |
| Aimmune Therapeutics, INC. | $27.42 | 2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $26.45 | 2019 | |
| Ironwood Pharmaceuticals, INC | $25.59 | 2020 | |
| Biogen, INC. | $24.65 | 2023 | Spinraza |
| Corcept Therapeutics | $18.51 | 2025 | Korlym |
| Redhill Biopharma INC. | $18.15 | 2020 | |
| Protega Pharmaceutials INC | $17.39 | 2024 | Roxybond |
| Mannkind Corporation | $14.93 | 2019 | |
| Cranial Technologies, INC | $14.17 | 2021 | |
| Optos, INC. | $14.00 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Kowa Pharmaceuticals America, INC. | $13.51 | 2025 | Zoryve |
| Shield Therapeutics INC | $13.18 | 2022 | |
| Amarin Pharma, INC. | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sultan Mohammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.